• RESULTS: There were significant differences in IOP 
INTRODUCTION
C urrently, filtration surgery, in which the aqueous humour can be drained from the anterior chamber to the bleb formed by the subconjunctival space by creating a guarded fistula, thus resulting in reduction of intraocular pressure (IOP). Filtration surgery is one of the most commonly performed surgical interventions for glaucoma patients who cannot be adequately controlled with medication or laser treatment. Trabeculectomy and ExPress implant surgery, both of which have the same efficacy at reducing IOP [1] , are the most common procedures during filtration surgery.
An excessive wound healing response, which gives rise to post-operative subconjunctival and Tenon's capsule scarring through fibroblast proliferation, migration, and contraction, is the main reason for failed filtration surgery [2] . Therefore, increased use of agents, such as 5-fluorouracil (5-FU) and mitomycin-C (MMC), is required to suppress fibroblast activity and increase the success rate of filtration surgery [3] . There is a higher incidence of adverse effects associated with these drugs, including corneal epithelial stripping [4] , cystic avascular blebs, bleb leakage, bleb infections, and endophthalmitis [5] .
It is well-known that anti-vascular endothelial growth factor (VEGF) antibodies can serve as an alternative anti-proliferative and anti-angiogenic agent [6] associated with the precise effect at wound modulation of the filtering bleb, and with fewer adverse effects. Currently, conbercept [conbercept ophthalmic injection, 10 mg/mL (0.2 mL); Chengdu Kanghong Biotechnologies Co. Ltd., Chengdu, China] is the latest anti-VEGF antibody and a recombinant fusion protein, the vital area of which is composed of the 2 nd Ig domain of human VEGFR1, the 3 rd and 4 th Ig domains of VEGFR2, and the constant Fc region of human IgG1 [7] . Moreover, conbercept has a higher binding affinity than natural decoys and monoclonal antibody, and is able to block all isoforms of VEGF-A, VEGF-B, and PIGF. Conbercept had puissant anti-angiogenic and anti-tumor effects by inhibiting VEGF in vitro and in vivo [8] . Some studies have demonstrated the anti-proliferative effects in a variety of anti-VEGF antibodies, such as ranibizumab and bevacizumab [6] . Until now, there have not been any reports demonstrating whether or not conbercept, which is the least expensive anti-VEGF antibody in China, has anti-proliferative action. This study outlines whether or not conbercept has any effects on scarring of filtration blebs, the variation in the IOP, the number of medicines, and the bleb characteristics using the Moorfields bleb grading system (MBGS) [9] for patients with glaucoma after filtration surgery. , 2018, and were randomly divided into the conbercept and 5-FU groups according to stratified blocked randomization using a random number table (Zhang J). If both eyes were eligible, only the more seriously affected eye was included. The inclusion criteria were as follows: 1) OAG with uncontrolled IOP by maximum tolerated drugs (>21 mm Hg any time during a 24-hour period, or a >8 mm Hg average daily fluctuation in IOP); 2) poor compliance to medical treatment giving rise to the high probability of glaucoma progression; and 3) progressively glaucomatous optic disc changes or visual field loss. The exclusion criteria were as follows: 1) other ocular comorbidities, such as keratonosus, lens dislocation, uveitis, retinal diseases, congenital anomalies, or ocular trauma; 2) allergic to conbercept; 3) uncontrolled diabetes or hypertension, or other medical conditions increasing the risk of complications from filter surgery; 4) pregnant or breastfeeding women; and 5) unable to accept the follow-up schedule. All filtration surgeries were operated by the same surgeon (Ke M) according to the following protocol [10] . A 1-mL syringe with a 29-gauge needle (Ultra-Fine Then, a wet swab was applied to seal the point following needle removal. Antibiotic eye ointment was instilled in the conjunctival sac and the eye was patched. Topical tobramycin and dexamethasone eye drops were used 4 times per day for 2wk and tapered off slowly for the following 4-6wk after filtration surgery. All the patients were examined routinely by the same examiner (Wang Q) blinded pre-operatively and 1d, 1wk, HD-OCT 4000; Carl Zeiss Meditec, Inc.). For this analysis, the IOP, number of medications used, type of conjunctival bleb, and complications were recorded by the same investigator (Chen DL) blinded. Conjunctival bleb morphology was graded according to the MBGS grading system by the observer. When describing a bleb, the following three most important aspects were considered: area; height; and vascualarity [9] . Statistical Analysis The data analysis was performed using SPSS software (version 20.0; SPSS, Inc., Chicago, IL, USA). Independent and paired t-tests were used to evaluate between groups. Proportion material was analyzed using Pearson χ 2 tests. A P-value <0.05 was considered statistically significant (Wang P) blinded.
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RESULTS
The baseline characteristics of all patients are given in Table 1 . There was no statistically significant difference in baseline characteristics between the two groups. All of the patients were of Han ethnicity. All of the patients had follow-up evaluations. The IOPs between the two groups pre-operatively and 1d, 1w, 1, 3 and 6mo post-injection are summarized in Table 2 . In the conbercept group, a statistically significant difference was detected in terms of IOP between pre-operatively compared with 1d (t=23.027, P=0.000), 1wk (t=20.805, P=0.000), 1mo (t=19.806, P=0.000), 3mo (t=17.824, P=0.000), and 6mo post-injection (t=15.717, P=0.000). Reduction in the IOP pre-operatively compared with 1d (t=18.851, P=0.000), 1wk (t=17.807, P=0.000), 1mo (t=13.999, P=0.000), 3mo (t=13.259, P=0.000), and 6mo post-injection (t=12.469, P=0.000) was statistically significant for the 5-FU group. The number of medications pre-operatively and 6mo postinjection in both groups is presented in Table 3 . Remarkable differences were observed pre-operatively compared with 6mo post-injection in the conbercept (t=21.658, P=0.000) and 5-FU groups (t=14.247, P=0.000). At 6mo post-injection, a significant difference was not demonstrated between the two groups (t=1.312, P=0.200), although the number of medications in the conbercept group was less than the 5-FU group. The types of conjunctival bleb pre-injection, and 1d, 1wk, 1, 3 and 6mo post-injection in both groups were compared in Table 4 . One day post-injection there were significant differences in vascularity 3a (t=8.497, P=0.000), 3b (t=6.693, P=0.000), and 3c (t=4.515, P=0.000). One week postinjection striking differences were observed in vascularity 3a (t=3.431, P=0.002), 3b (t=6.408, P=0.000), and 3c (t=3.984, P=0.000). The same results were noted in vascularity 3a, 3b (either t=2.466, P=0.019), and 3c (t=2.503, P=0.017) 1mo post-injection; however, remarkable differences from other indicators were not observed. 
.596, P=0.206). In both groups, no transient anterior chamber shallowing, endophthalmitis, and hypotony was reported. DISCUSSION It is well-documented that one of the common reasons for failing to control IOP is excessive wound healing and overscarring after filtration surgery, which may occur at the surfaces of the Tenon capsule, under the conjunctiva, and above the intermediate episclera; the failure rate can reach 15%-30% [5, [12] [13] . Fibroblasts, which play a significant role in scar formation in filtering blebs, are regarded as the primary effector cells of wound healing and in the Tenon capsule [12] . Furthermore, according to some reports, use of IOP-lowering medications pre-operatively >1y is associated with a prominent increase in the content of granulocyte-macrophage colony, other inflammatory cells, and fibroblasts in the conjunctiva and Tenon capsule specimen of filtering surgery [14] . Also, there is an increased rate of IOP dysregulation, lower achievement ratio of surgery, and higher frequency of filtering bleb scarring [15] for the same patients post-operatively. Maximum proliferation of subconjunctival fibroblasts are detected in histologic studies on the 3 rd -5 th post-operative days [13] . Currently, the most frequently used anti-proliferative drugs which inhibit scarring are 5-FU and MMC. There is a definite therapeutic effect, but there are some side effects associated with 5-FU and MMC, such as corneal epithelial stripping, bleb leakage, transient anterior chamber shallowing, and encapsulated blebs [11, 13, 16] . of conjunctival bleb on pre-injection, post-injection 1d, 1wk, 1, 3 and 6mo in both Therefore, a safe agent with low toxicity has long been an important matter for filtration surgery of OAG. Cheng et al [17] reported that bevacizumab improves the outcome of filtration surgery and reduces complications significantly. Furthermore, bevacizumab dramatically inhibited the angiogenic factor (VEGF) and inflammation factors (TGF-β 1 and TGF-β 2 ). Noh et al [18] reported that ranibizumab, as an angiogenesis inhibitor, could inhibit fibroblast proliferation and migration from the human Tenon capsule in vitro. Sufficient evidence has demonstrated that VEGF has an effect on fibroblastic activity, not only via angiogenesis, but also directly [19] . Regarded as a mediator and regulator [20] , VEGF promotes inflammatory cells to reach the center of the reparative process, which increases fibroblasts migration. The higher the VEGF levels in the aqueous of glaucoma patients who have undergone filtration surgery, as well as the levels of other cytokines, the higher the risk of scarring [13, 17] . It has been demonstrated from recent surveys that angiogenesis inhibitors impact scar formation in the skin by altering collagen deposition and reducing wound healing [21] , which improves the density of blood vessels by increasing the content of VEGF [22] . Therefore, an anti-VEGF drug which restrains not only neovascularization, but also suppresses scar formation enhances its efficacy. Ming et al [23] had reported 7-17d in the holding aspect and 11.93±2.23d in average survival time for filtering blebs on the surface of vascularization in rats. Concurrently, proliferating fusiform or star-shaped fibroblasts were noted 5d postoperatively and expanding blood vessels upon the filtering bleb were discovered 7d post-operatively. Given these findings, the designers chose to inject the drug into the subconjunctiva on the 5 th day post-operatively to inhibit vascularization and fibroblast proliferation. Also, the complications from the subconjunctival injection of anti-VEGF drugs, such as bevacizumab and ranibizumab, were fewer than anti-proliferative drugs. Akkan and Cilsim [24] indicated that there was inhibition on scar formation of filtering blebs after filtration surgery for glaucoma patients; however, it was incontestable that the drugs were too expensive in China. The newest and less expensive anti-VEGF drug (conbercept) is affordable. Therefore, we made a plan to determine whether or not conbercept is safe and effective in suppressing the scarring process through subconjunctival injection after filtration surgery.
In our study, significant reductions of IOPs were reported 1d, 1wk, 1, 3 and 6mo post-injection in comparison with preoperatively in the conbercept group. There were significant decreases in IOPs in the conbercept group in comparison with the 5-FU group 1, 3 and 6mo post-injection. Moreover, 6mo post-injection the number of medications for decreasing IOP was less than pre-operatively in each group; however, there was no statistical diversity observed between both groups 6mo post-injection. Moreover, there were less values of vascularity 3a, 3b, and 3c in the conbercept group than the 5-FU group 1d, 1wk, and 1mo post-injection. Simultaneously, the statistical differences between the two groups for other indices, such as bleb area 1a, 1b, and height, at the same viewing time were not demonstrated. There was more frequent corneal epithelial stripping in the 5-FU group than the conbercept group. Hence, the congestion extent of filtering blebs and conjunctiva was distinct prior to 5-FU, although there were no noticeable differences in alleviating IOP, number of medications, and bleb area 1a, 1b and height between subconjunctival injection of conbercept and 5-FU for OAG patients undergoing filtration surgery who had used long-term lowering IOP medications. There were fewer complications for subconjunctival injection of conbercept than 5-FU. In summary, nearly all data proved that subconjunctival injection of conbercept has a safe, effective, and tolerable profile. Although our study provides insight into advantages of subconjunctival injection of conbercept for glaucoma after surgery, there is still some work to be done, such as comparing the curative effect of the other anti-VEGF drugs (bevacizumab or ranibizumab), increasing the number of clinical samples and lengthening the observation time.
